STOCK TITAN

Ginkgo Bioworks Announces Participation in 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

BOSTON, Jan. 5, 2022 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that Co-Founder and CEO Jason Kelly is scheduled to participate in a presentation at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022 at 3:45 p.m. Eastern Time.

Further details, a webcast link, and a replay of the presentation will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.

About Ginkgo Bioworks

Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization, and therapeutics discovery. For more information, visit www.ginkgobioworks.com.

Ginkgo Bioworks Contacts:

INVESTOR CONTACT:

investors@ginkgobioworks.com  

MEDIA CONTACT:

press@ginkgobioworks.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-announces-participation-in-40th-annual-jp-morgan-healthcare-conference-301454238.html

SOURCE Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

DNA Rankings

DNA Latest News

DNA Stock Data

1.46B
1.12B
6.74%
83.82%
12.58%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BOSTON

About DNA

the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.